Published June 2011 | Version public
Journal Article

X-chromosome epigenetic reprogramming in pluripotent stem cells via noncoding genes

  • 1. ROR icon California Institute of Technology
  • 2. ROR icon Massachusetts General Hospital
  • 3. ROR icon Harvard University

Abstract

Acquisition of the pluripotent state coincides with epigenetic reprogramming of the X-chromosome. Female embryonic stem cells are characterized by the presence of two active X-chromosomes, cell differentiation by inactivation of one of the two Xs, and induced pluripotent stem cells by reactivation of the inactivated X-chromosome in the originating somatic cell. The tight linkage between X- and stem cell reprogramming occurs through pluripotency factors acting on noncoding genes of the X-inactivation center. This review article will discuss the latest advances in our understanding at the molecular level. Mouse embryonic stem cells provide a standard for defining the pluripotent ground state, which is characterized by low levels of the noncoding Xist RNA and the absence of heterochromatin marks on the X-chromosome. Human pluripotent stem cells, however, exhibit X-chromosome epigenetic instability that may have implications for their use in regenerative medicine. XIST RNA and heterochromatin marks on the X-chromosome indicate whether human pluripotent stem cells are developmentally 'naïve', with characteristics of the pluripotent ground state. X-chromosome status and determination thereof via noncoding RNA expression thus provide valuable benchmarks of the epigenetic quality of pluripotent stem cells, an important consideration given their enormous potential for stem cell therapy.

Additional Information

© 2011 Elsevier Ltd. Available online 3 March 2011. We thank all laboratory members for valuable discussions. D.H.K. is supported by a Damon Runyon Cancer Research Foundation Fellowship (DRG-#2027-09) and the Beckman Fellows Program at Caltech, Y.J. by a Korean Research Foundation grant (C00069) and a Discovery grant from MGH ECOR, M.C.A. by NIH T32CA009216, and J.T.L. by NIH-GM58839. J.T.L is an Investigator of the Howard Hughes Medical Institute.

Additional details

Identifiers

Eprint ID
27280
DOI
10.1016/j.semcdb.2011.02.025
Resolver ID
CaltechAUTHORS:20111018-111436796

Funding

Damon Runyon Cancer Research Foundation Fellowship
2027-09
Caltech Beckman Fellows Program
Korean Research Foundation
C00069
NIH
T32CA009216
NIH
GM58839
MGH ECOR Discovery Grant

Dates

Created
2011-10-18
Created from EPrint's datestamp field
Updated
2021-11-09
Created from EPrint's last_modified field